In conclusion, here, we showed prospectively and in a consistent number of CML patients that CML-specific CD26+LSCs may persist at a very low level during TFR, nevertheless allowing patients to live TKI-free and without experiencing a molecular relapse. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.